口腔细菌微生物群促进了性结肠炎患者口腔的分层
Jun Xu1,2, Yu Zhang1,2, Xiao-Hui Fang1,2
1Department of Gastroenterology, Peking University People's Hospital, No.11, Xizhimen South Street, Xicheng District, Beijing, 100044, China.
Annals of clinical microbiology and antimicrobials
|November 10, 2023
概括
口腔细菌可能表明,口腔的性结肠炎患者的治疗反应. 监测口腔微生物群可以帮助评估这些患者的治疗结果.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 口腔医学是指口腔医学.
背景情况:
- 炎症性肠病 (IBD) 经常涉及口腔病变.
- 在IBD中已知有口腔微生物失生症,但在IBD患者中,口腔的胃肠道细菌仍然没有表征.
研究的目的:
- 分析胃肠道中的细菌群体,包括有或没有口腔的性结肠炎 (UC) 患者.
- 调查口腔和便微生物群与UC患者治疗反应之间的关系.
主要方法:
- 来自健康对照组,口腔患者和UC患者 (有或没有口腔) 的唾液,口腔和样的16SrRNA V3-V4测序.
- 在不同的胃肠道中比较细菌的数量和生物功能.
- 用5-氨基酸盐 (5-ASA) 治疗UC患者的六个月随访,以评估治疗反应.
主要成果:
- 与唾液和口腔微生物相比,便微生物群显著影响宿主免疫系统.
- 患有口腔的UC患者对5-ASA治疗的反应较弱.
- 三种口腔细菌系 (Fusobacterium,Oribacterium,Campylobacter) 可能与治疗反应有关,唾液微生物组表明5-ASA治疗反应.
结论:
- 口腔微生物群可以帮助分层性结肠炎患者口腔.
- 口腔微生物群有可能反映UC患者的治疗反应.
- 监测像Fusobacterium,Oribacterium和Campylobacter这样的口腔细菌可能有价值,以评估口腔的UC患者的治疗反应.
相关概念视频
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
438
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
438
01:26Peptic Ulcer Disease IV: Management
96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
01:30Peptic Ulcer Disease I: Introduction
179
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
179
01:29Drugs for Treatment of Ulcerative Colitis in IBD
146
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
146
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
515
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
515
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
192
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
192